#JOPLIN GLOBE CLASSIFIEDS SKIN#

Changes in glucometrics and HbA1c were evaluated. In this multi-center study, CGM naive patients were followed for 6 months of self-monitoring of blood glucose (SMBG) followed by 6 months of Eversense CGM System use (90-day Eversense transitioning to Eversense E3 CGM System after FDA approval). The feasibility study of the next generation Eversense Sensor showed the system could provide accurate performance through a 365-day period.ĪDA Poster Presentation – Glycemic Improvements in CGM Naive Patients during SMBG and Implantable CGM Use presented by Katherine Tweden, PhD MARD observed for the modified CGM system through 365 days was similar to that observed with Eversense E3 CGM System through 180 days

#JOPLIN GLOBE CLASSIFIEDS SKIN#

The sensor was safe with few minor skin irritation adverse events Sensor longevity was 97% through 365 days “We are thankful for the opportunity to present these results to our peers at the American Diabetes Association Scientific Sessions and are proud to support the global diabetes community with a CGM that provides safety and accuracy benefits that can lead to more effective diabetes management.”ĪDA Oral Presentation – Results for Accuracy Evaluation of an Implantable CGM with Chemistry Improvements in a 365-Day Feasibility Study presented by Lujain Al-KhawiĪ feasibility study was conducted in 32 patients using a modified Eversense CGM System to assess if longevity could be extended through 365 days while maintaining accuracy. These recent studies are an important step forward as we continue to expand awareness of the system’s unique clinical benefits,” said Francine Kaufman, M.D., Senseonics Chief Medical Officer. “These data further bolster Eversense’s position as a leading CGM choice for people with diabetes. Two studies were presented demonstrating the safety and accuracy of the Eversense E3 CGM system. (NYSE-American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today highlighted new clinical data presented at the American Diabetes Association 83 rd Scientific Session. GERMANTOWN, Md.-( BUSINESS WIRE)-Senseonics Holdings, Inc.

Joplin globe classifieds